+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Peptide Therapeutics Market by Type of Peptide, Route of Administration, Key Geographical Regions and Key Therapeutic Area: Industry Trends and Global Forecasts, 2021 - 2030

  • ID: 5359094
  • Report
  • April 2021
  • Region: Global
  • 250 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 13therapeutics
  • BioMarin Pharmaceutical
  • F4 Pharma
  • KeyBioscience
  • OrbiMed
  • Sarsia Seed

Overview

Over the years, the rising popularity of biologics, such as peptide therapeutics, have led to an evident shift in the focus of the healthcare industry, from traditional small molecule-based interventions to upcoming, albeit complex, family of pharmacological interventions. The success of peptide therapeutics, so far, can be attributed to their clinical benefits, which include high target specificity, low toxicity and favorable safety profiles. Since 2017, over 10 peptide-based drugs have received marketing approvals across different regions of the world.  Examples of recently approved peptide drugs include (in the reverse chronological order of approval) Lupkynis™ (2021), Mycappsa® (2020), Scenesse® (2019), Rybelsus® (2019) and Vyleesi® (2019). Further, more than 150 therapeutic peptides are currently under clinical investigation, while several novel leads are being evaluated in the early stages of research. In this context, it is also worth mentioning that peptide-based therapy products account for 5% of the global pharmaceutical revenues generated annually.  

Presently, several drug developers, along with technology providers, are actively engaged in the development of novel peptide therapeutics, such as peptide drug conjugates and cell penetrating peptides. Innovation in this field of research is mostly focused on improving drug delivery methods, API stability, target affinity, and optimizing toxicity profiles. Several big pharma players have also demonstrated interest in peptide therapeutics and are investing both time and capital in this domain. Since 2019, more than USD 3 billion has been invested into companies that are involved in the development of various types of peptide drugs. In addition, the market is witnessing significant partnership activity; several licensing agreements, focused on drug development and commercialization, were recently inked between stakeholders in this industry. 

Scope of the Report

The “Peptide Therapeutics Market by  Type of Peptide (Small, Medium and Large), Route of Administration (Intravenous, Oral, Subcutaneous, Topical and Others), Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World) and Key Therapeutic Area (Metabolic Diseases, Oncological Diseases, Endocrine Diseases, Digestive and Gastrointestinal Diseases and Others): Industry Trends and Global Forecasts, 2021 – 2030” report features an extensive study of the current market landscape of peptide therapeutics. The study also includes an elaborate discussion on the future potential of this evolving market. 

Amongst other elements, the report features:

  • A detailed review of the overall market landscape of peptide-based therapies, including information on their current phase of development (marketed, clinical, preclinical and discovery), type of peptide (small, medium and large), route of administration (intravenous, oral, subcutaneous, topical and others) and key therapeutic area.
  • A detailed review of the players engaged in the development of peptide drugs, along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of prominent players engaged in the development of peptide therapeutics. Each profile features a brief overview of the company, details related to its financials (if available), product portfolios, recent developments and an informed future outlook.
  • An analysis of the big pharma players engaged in this domain, featuring a heat map representation, based on relevant parameters, such as number of therapeutic peptides under development, information on funding, partnership and clinical trials activity.
  • An analysis of the recent collaborations (signed since 2015) focused on peptide therapeutics, based on relevant parameters, such as the year in which the agreement was signed, type of agreement, type of peptide, route of administration, phase of development and therapeutic area. 
  • An analysis of various investments, such as seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other equity offerings, that were undertaken by companies engaged in this domain, between 2015-2021.
  • An in-depth analysis of completed, ongoing, and planned clinical studies of various peptide therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication and key geographical regions.
  • An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III), based on several relevant parameters, such as size of enrolled patient population (for the trial in the highest phase of development), route of administration, type of therapy, dosing frequency (for quantifying clinical attractiveness), target patient population, expected launch date and size of developer company (for quantifying commercial attractiveness).
  • A case study on the role of service providers that operate within the peptide therapeutics market, along with information on the various CROs, CMOs and custom peptide manufacturers that are actively engaged in this segment. 
  • A case study presenting the key characteristics of novel peptide therapeutics, along with information on their applications and advantages, as well as key challenges associated with their development process.

One of the key objectives of the report was to estimate the existing market size and future opportunity associated with peptide therapeutics, over the next decade. Based on the sales for approved peptide drugs, during the period 2015-2020, we have developed informed estimates on the evolution of the market over the coming decade. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of peptide (small, medium and large), [B] route of administration (intravenous, oral, subcutaneous, topical and others), [C] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World) and [D] key therapeutic area (metabolic diseases, oncological diseases, endocrine diseases, digestive and gastrointestinal diseases and others). In addition, the report provides value creation analysis of approved and clinical peptide-based therapies across different therapeutic areas.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry players engaged in the development of peptide therapeutics? 
  • Which key disease indications are targeted by peptide therapeutic candidates in the current development pipeline? 
  • What are the different initiatives undertaken by big pharma players for the development of peptide therapeutics in the recent past? 
  • What kind of partnership models are most commonly adopted by stakeholders engaged in this domain?
  • Who are the key stakeholders that have actively made investments in the peptide therapeutics domain?
  • How is the current and future market opportunity likely to be distributed across key market segments?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 13therapeutics
  • BioMarin Pharmaceutical
  • F4 Pharma
  • KeyBioscience
  • OrbiMed
  • Sarsia Seed

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3 INTRODUCTION
3.1. Chapter Overview
3.2. Structure of Peptides
3.3. Classification of Peptides
3.4. Modification of Peptides
3.4.1. N-Terminal Modifications
3.4.2. Internal Modifications
3.4.3. C-Terminal Modifications
3.4.4. Other Modifications 
3.5. Evolution of Peptide Therapeutics
3.6. Design and Development of Peptide Therapeutics
3.6.1. Traditional versus Novel Peptide Technologies
3.7. Advantages and Disadvantages of Peptide Therapeutics
3.8. Applications of Peptide Therapeutics
3.9. Future Perspectives

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Peptide Therapeutics: Overall Market Overview
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Peptide
4.2.3. Analysis by Route of Administration
4.2.4. Analysis by Phase of Development and Route of Administration
4.2.5. Analysis by Therapeutic Area
4.2.6. Analysis by Phase of Development and Therapeutic Area
4.2.7. Analysis by Route of Administration and Therapeutic Area
4.2.8. Analysis by Phase of Development, Route of Administration and Therapeutic 

5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Peptide Therapeutics: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Phase of Development and Geography (Logo Landscape)
5.2.4. Key Players: Analysis by Number of Product Candidates
5.3. Analysis by Company Size, Phase of Development and Geography (Heat Map 

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Apellis Pharmaceuticals
6.2.1 Company Overview
6.2.2. Financial Information
6.2.3 Pipeline Details
6.2.4. Recent Developments and Future Outlook
6.3. BioLineRx
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Pipeline Details
6.3.4. Recent Developments and Future Outlook
6.4. Eli Lilly
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Pipeline Details
6.4.4. Recent Developments and Future Outlook
6.5. FirstString Research
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Pipeline Details
6.5.4. Recent Developments and Future Outlook
6.6. Novo Nordisk
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Pipeline Details
6.6.4. Recent Developments and Future Outlook
6.7. Palatin Technologies
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Pipeline Details
6.7.4. Recent Developments and Future Outlook
6.8. RegeneRx Biopharmaceuticals
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Pipeline Details
6.8.4. Recent Developments and Future Outlook
6.9. Stealth BioTherapeutics
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Pipeline Details
6.9.4. Recent Developments and Future Outlook
6.10. Takeda
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Pipeline Details
6.10.4. Recent Developments and Future Outlook
6.11. Zealand Pharma
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Pipeline Details
6.11.4. Recent Developments and Future Outlook

7. PEPTIDE THERAPEUTICS FOCUSED INITIATIVES OF BIG PHARMA 
7.1. Chapter Overview
7.2. Top Pharmaceutical Companies: Peptide Therapeutics Focused Initiatives
7.2.1. Analysis by Number of Amino Acids 
7.2.2. Analysis by Route of Administration
7.2.3. Analysis by Therapeutic Area 
7.3. Benchmark Analysis of Key Parameters
7.3.1. Spider Web Analysis: Pipeline Strength
7.3.2. Spider Web Analysis: Partnerships
7.3.3. Spider Web Analysis: Investments
7.3.4. Spider Web Analysis: Clinical Trials
7.4. Benchmark Analysis of Big Pharmaceutical Players
7.4.1. Spider Web Analysis: Novo Nordisk
7.4.2. Spider Web Analysis: Amgen
7.4.3. Spider Web Analysis: Takeda
7.4.4. Spider Web Analysis: Eli Lilly
7.4.5. Spider Web Analysis: Johnson and Johnson

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Peptide Therapeutics: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership 
8.3.3. Analysis by Year and Type of Partnership 
8.3.4. Analysis by Type of Peptide 
8.3.5. Analysis by Route of Administration
8.3.6. Analysis by Type of Partnership and Route of Administration
8.3.7. Analysis by Type of Partnership, Type of Peptide and Route of Administration
8.3.8. Analysis by Phase of Development
8.3.9. Analysis by Type of Partnership and Phase of Development
8.3.10. Analysis by Therapeutic Area
8.3.11. Analysis by Year, Type of Partnership and Therapeutic Area (Grid 
8.4. Most Active Players: Analysis by Number of Partnerships
8.5. Regional Analysis
8.5.1. Intracontinental and Intercontinental Agreements
8.5.2. Local and International Agreements

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Peptide Therapeutics: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Year and Type of Funding 
9.3.5. Analysis of Amount Invested by Geography
9.3.6. Most Active Players: Analysis by Number of Funding Instances and Amount 
9.3.7. Key Investors: Analysis by Number of Funding Instances
9.3.8. Analysis by Phase of Development
9.3.9. Analysis by Therapeutic Area

10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Peptide Therapeutics: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Phase
10.3.4. Analysis by Trial Recruitment Status
10.3.5. Analysis by Trial Registration Year and Enrolled Patient Population
10.3.6. Analysis by Study Design
10.3.7. Analysis by Type of Sponsor / Collaborator
10.3.8. Most Active Players: Analysis by Number of Registered Trials
10.3.9. Emerging Focus Area
10.3.10. Analysis by Therapeutic Area
10.3.11. Geographical Analysis by Number of Registered Trials
10.3.12. Geographical Analysis by Enrolled Patient Population

11. CLINICAL AND COMMERCIAL ATTRACTIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Methodology
11.2.1. Assumptions and Key Parameters
11.3. Affiliated Insights
11.3.1. Clinical and Commercial Attractiveness Analysis: Autoimmune Diseases
11.3.2. Clinical and Commercial Attractiveness Analysis: Cardiovascular Diseases
11.3.3. Clinical and Commercial Attractiveness Analysis: Central Nervous System 
11.3.4. Clinical and Commercial Attractiveness Analysis: Digestive and Gastrointestinal  
11.3.5. Clinical and Commercial Attractiveness Analysis: Endocrine Diseases
11.3.6. Clinical and Commercial Attractiveness Analysis: Genetic Diseases
11.3.7. Clinical and Commercial Attractiveness Analysis: Hematological Diseases
11.3.8. Clinical and Commercial Attractiveness Analysis: Infectious Diseases
11.3.9. Clinical and Commercial Attractiveness Analysis: Inflammatory Diseases
11.3.10. Clinical and Commercial Attractiveness Analysis: Metabolic Diseases
11.3.11. Clinical and Commercial Attractiveness Analysis: Oncological Diseases
11.3.12. Clinical and Commercial Attractiveness Analysis: Ophthalmic Diseases
11.3.13. Clinical and Commercial Attractiveness Analysis: Other Diseases

12. CASE STUDY: CONTRACT SERVICES LANDSCAPE 
12.1.1. Chapter Overview
12.2. Role of Service Providers
12.2.1. List of Peptide CROs
12.2.2. List of Platform Providers
12.2.3. List of Peptide CMOs
12.2.3.1. List of Custom Peptide Manufacturers
12.3. Advantages of Outsourcing
12.4. Risks and Challenges Associated with Outsourcing

13. CASE STUDY: NOVEL PEPTIDE THERAPEUTICS
13.1. Chapter Overview
13.2. Overview of Novel Peptide Therapeutics
13.3. Advantages and Applications of Novel Peptide Therapeutics
13.4. Key Challenges Associated with Novel Peptide Therapeutics

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology
14.4. Global Peptide Therapeutics Market, 2021-2030
14.4.1. Global Peptide Therapeutics Market, 2021-2030: Distribution by Type of Peptide
14.4.2. Peptide Therapeutics Market, 2021-2030: Distribution by Number of Amino 
14.4.3. Peptide Therapeutics Market, 2021-2030: Distribution by Route of 
14.4.4. Peptide Therapeutics Market, 2021-2030: Distribution by Geography
14.4.5. Peptide Therapeutics Market, 2021-2030: Distribution by Key Therapeutic Area
14.5. Autoimmune Diseases
14.5.1. Value Creation Analysis
14.5.2. Sales Forecast for Approved Peptide Therapeutics
14.5.2.1. Tymlos ®
14.5.3. Sales Forecast for Clinical Peptide Therapeutics
14.5.3.1. Ampion / DMI 9523
14.5.3.2. TBRIA
14.6. Cardiovascular Diseases
14.6.1. Value Creation Analysis
14.6.2. Sales Forecast for Clinical Peptide Therapeutics
14.6.2.1. Giapreza ®
14.6.2.2. Kalbitor ®
14.6.3. Sales Forecast for Clinical Peptide Therapeutics
14.6.3.1. Elamipretide / MTP-131
14.6.3.2. Nerinetide
14.7. CNS Diseases
14.7.1. Value Creation Analysis
14.7.2. Sales Forecast for Clinical Peptide Therapeutics
14.7.2.1. Rybelsus ®
14.8. Dermatological Diseases
14.8.1. Value Creation Analysis
14.8.2. Sales Forecast for Approved Peptide Therapeutics
14.8.2.1. Melgain
14.9. Digestive and Gastrointestinal Diseases
14.9.1. Value Creation Analysis
14.9.2. Sales Forecast for Approved Peptide Therapeutics
14.9.2.1. Gattex ®
14.9.2.2. Trulance ®
14.9.3. Sales Forecast for Clinical Peptide Therapeutics
14.9.3.1. Glepaglutide / ZP1848
14.9.3.2. INN-202 / Larazotide
14.10. Endocrine Diseases
14.10.1. Value Creation Analysis
14.10.2. Sales Forecast for Approved Peptide Therapeutics
14.10.2.1. Parsabiv ®
14.10.2.2. Lupykins
14.10.3. Sales Forecast for Clinical Peptide Therapeutics
14.10.3.1. Difelikefalin / KORSUVA / Oral CR845
14.11. Genetic Diseases
14.11.1. Value Creation Analysis
14.11.2. Sales Forecast for Approved Peptide Therapeutics
14.11.2.1. Scenesse ®
14.11.3. Sales Forecast for Clinical Peptide Therapeutics
14.11.3.1. BMN 111 / Vosoritide 
14.11.3.2. Ninlaro ® 
14.11.3.3. RA101495 / Zilucoplan
14.12. Hematological Diseases
14.12.1. Value Creation Analysis
14.12.2. Sales Forecast for Clinical Peptide Therapeutics
14.12.2.1. APL-2 / Pegcetacoplan 
14.13. Infectious Diseases
14.13.1. Value Creation Analysis
14.13.2. Sales Forecast for Approved Peptide Therapeutics
14.13.2.1. Solnatide
14.13.3. Sales Forecast for Clinical Peptide Therapeutics
14.13.3.1. Aikening / Albuvirtide
14.13.3.2. Reltecimod
14.14. Inflammatory Diseases
14.14.1. Value Creation Analysis
14.14.2. Sales Forecast for Clinical Peptide Therapeutics
14.14.2.1. Lupuzor 
14.15. Metabolic Diseases
14.15.1. Value Creation Analysis
14.15.2. Sales Forecast for Approved Peptide Therapeutics
14.15.2.1. Adlyxin ®
14.15.2.2. Trulicity ®
14.15.2.3. Mycapssa ®
14.15.2.4. Rybelsus ®
14.15.2.5. Ozempic ®
14.15.2.6. Sandostatin ®
14.15.2.7. Imcivree ™
14.15.2.8. Tanzeum ®
14.15.2.9. Tresiba ®
14.15.3. Sales Forecast for Clinical Peptide Therapeutics
14.15.3.1. Dasiglucagon
14.15.3.2. Granexin
14.15.3.3.  Imcivree ™
14.15.3.4. Ozempic
14.15.3.5. Relamorelin
14.15.3.6. Tirzepatide / LY3298176
14.16. Oncological Diseases
14.16.1. Value Creation Analysis
14.16.2. Sales Forecast for Approved Peptide Therapeutics
14.16.2.1. Aplidin ®
14.16.2.2. Lupron ®
14.16.2.3. Lutathera ®
14.16.2.4. Ninlaro ®
14.16.3. Sales Forecast for Clinical Peptide Therapeutics
14.16.3.1. Balixafortide / POL6326
14.16.3.2. BL-8040 / Motixafortide
14.16.3.3. Dusquetide / SGX942
14.17. Ophthalmic Diseases
14.17.1. Value Creation Analysis
14.17.2. Sales Forecast for Clinical Peptide Therapeutics
14.17.2.1. APL-2 / Pegcetacoplan
14.17.2.2. GBT-201 / RGN-259
14.17.2.3. XG-102
14.18. Respiratory Diseases
14.18.1. Value Creation Analysis
14.18.2. Sales Forecast for Approved Peptide Therapeutics
14.18.2.1. Solnatide
14.19. Other Diseases
14.19.1. Value Creation Analysis
14.19.2. Sales Forecast for Approved Peptide Therapeutics
14.19.2.1. Lupron ®
14.19.2.2. Vyleesi ™
14.19.2.3. Xylentra ™
14.19.3. Sales Forecast for Clinical Peptide Therapeutics
14.19.3.1. BP-101
14.19.3.2. Granexin
14.19.3.3. Ensereptide / PXL01

15. CONCLUDING REMARKS
15.1. Chapter Overview

16. APPENDIX I: LIST OF APPROVED PEPTIDE THERAPEUTICS (2000-2012)

17. APPENDIX II: TABULATED DATA

18. APPENDIX III: LIST OF COMPANIES AND ORGANIZATIONS

Note: Product cover images may vary from those shown
  • 13therapeutics
  • 7 Med Health Ventures
  • 9 Meters Biopharma
  • Abbott
  • Abingworth
  • Acorn Bioventures
  • ACT Capital Management
  • Adage Capital Management
  • Adams Street Partners
  • Advanced Accelerator Applications
  • Aileron Therapeutics
  • AJU IB Investment
  • Akashi Therapeutics
  • Alexion Pharmaceuticals
  • Allergan
  • Allysta Pharmaceuticals
  • Alphabet venture arm
  • Altimmune
  • Amgen
  • Amolyt Pharma
  • Ampio Pharmaceuticals
  • Amyndas Pharmaceuticals
  • Andera Partners
  • Angiochem
  • Anji Pharmaceuticals
  • AOP Orphan Pharmaceuticals
  • Apellis Pharmaceuticals
  • Apeptico
  • APIM Therapeutics
  • Apitope
  • Aquestive Therapeutics
  • Arch Biopartners
  • ARCH Venture Partners
  • Arix Bioscience
  • Asahi Kasei
  • AsclepiX Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Atlas Venture
  • Atox Bio
  • Aurinia Pharmaceuticals
  • Avilex Pharma
  • Avion Pharmaceuticals
  • Barer & Son Capital
  • Bayer
  • Becker 
  • Belfius
  • Bergens forskningsstiftelse
  • Beth Israel Deaconess Medical Center
  • Better Ventures
  • Bicycle Therapeutics
  • Biogenosis
  • Bioglan
  • BioLineRx
  • Biolingus
  • BioMarin Pharmaceutical
  • Biomedical Advanced Research and Development Authority (BARDA) 
  • BiomedInvest
  • BioMedPartners
  • Biomarck Pharmaceuticals
  • Bios Partners
  • Biosciences Research & Commercialization Center
  • BioSkin
  • BL&H
  • Boehringer Ingelheim
  • Boehringer Ingelheim Venture Fund
  • Boryung Pharmaceutical
  • Bossa Ventures
  • Boston Therapeutics
  • Bpifrance
  • Brightlands Life Sciences Ventures
  • Bristol Myers Squibb
  • Buttonwood
  • BVF Partners
  • Cambridge Innovation Capital (CIC)
  • Canaccord Genuity
  • Canadian Glycomics Network
  • CanBas
  • Cancer Research UK
  • Capital Community Angels
  • Cara Therapeutics
  • Cardiorentis
  • Carmot Therapeutics
  • Catalent
  • Cathay Venture
  • Celgene
  • Cellastra
  • Cend Therapeutics
  • Chiasma Pharma
  • Chondropeptix
  • Chrysalis BioTherapeutics
  • Clinical Research Center for Hair and Skin
  • Clinuvel Pharmaceuticals
  • CohBar
  • Cold Spring Harbor Laboratory
  • Constant Therapeutics
  • Contura
  • Cormorant Asset Management
  • CureDM
  • Curonz
  • Cutanea Life Sciences
  • Cystic Fibrosis Foundation Therapeutics
  • Cytovation
  • Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
  • Deerfield Management
  • Diabetology
  • Diapin Therapeutics
  • E&Investment
  • Eczacibasi
  • Elan Pharmaceuticals
  • Eli Lilly
  • Endo Ventures
  • Entera Bio
  • Enteris BioPharma
  • Epidarex Capital
  • Epimede
  • Eshelman Ventures
  • Esperance Pharmaceuticals
  • European Commission
  • F4 Pharma
  • Fannin Partners
  • Ferring Pharmaceuticals
  • First In Ventures
  • FirstString Research
  • Follicum
  • Foresite Capital
  • Founders Fund
  • Fountain Healthcare Partners
  • F-Prime Capital Partners
  • Frontier Biotechnologies
  • FUJIFILM Toyama Chemical
  • Genentech
  • Genervon Biopharmaceuticals
  • GeneScience
  • Genus Oncology
  • GF Ventures
  • Gila Therapeutics
  • GlaxoSmithKline
  • GlioCure
  • Google Ventures
  • Government of Canada
  • Government of Quebec
  • Grand Oaks Capital
  • G-tree BNT
  • Dana-Farber Cancer Institute
  • HBG Beteiligungs- und Beratungsgesellschaft
  • HealthCare Royalty Partners (HCR)
  • Healthlink Capital
  • Hercules Capital
  • Hestia Investments
  • HighTide Therapeutics
  • Hillhouse Capital Group
  • Horizon Technology Finance
  • Horizons Ventures
  • iBio
  • ILC Therapeutics
  • Imcyse
  • ImmuPharma
  • InCube Ventures
  • InFocus Capital Partners
  • InnoBio 2
  • Innovate UK
  • Inotrem
  • Integra Holdings
  • Inter-American Development Bank (IDB)
  • InterK Peptide Therapeutics
  • Intervest
  • Invest Michigan
  • Investinor
  • Invus
  • Ipsen
  • Ironwood Pharmaceuticals
  • Issar Pharmaceuticals
  • Janssen Biotech
  • Janssen Pharmaceuticals
  • JDRF
  • Johnson & Johnson
  • Kaitai Capital
  • Kalos Therapeutics
  • KeyBioscience
  • Knoll Capital Management
  • Korean Government
  • KPC Pharmaceuticals
  • Kreos Capital
  • KU Leuven
  • Kurma Partners
  • L1 Capital Global Opportunities Master Fund
  • La Jolla Pharmaceutical
  • Lanstead Capital
  • Lassogen
  • Lee's Pharmaceutical
  • Lincoln Park Capital Fund
  • Lind Global Macro Fund
  • LipimetiX Development
  • Live Like Bella® Foundation
  • Longevity Biotech
  • Longwood Fund
  • Lonza
  • LRM Funds
  • LSP
  • Lundbeckfonden Ventures
  • Madryn Asset Management
  • Maven Investment Partners
  • Maxim Group
  • MEDARVA Foundation
  • MedImmune
  • Mediolanum Farmaceutici
  • Megapharm
  • MElkin Pharmaceuticals
  • Merck
  • Merck Sharp & Dohme (MSD)
  • MeSCue-Janusys
  • Michigan Capital Network Venture Fund III
  • Mitsubishi Tanabe Pharma
  • Morningside Ventures
  • MPM Capital
  • Nan Fung Technology’s Pivotal Beta
  • Nanomerics
  • National Cancer Institute (NCI)
  • National Eye Institute (NEI)
  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Dental and Craniofacial Research (NIDCR)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • National Institutes of Health (NIH)
  • National Multiple Sclerosis Society
  • National Research Council Canada
  • NeuroRx
  • New Enterprise Associates
  • NextPharma
  • NoNO
  • Noshaq
  • NovaCell Technology
  • Novartis
  • Novartis Venture Fund
  • Novo Nordisk
  • Novo Ventures
  • NV Industriebank LIOF
  • Oncology Pharma
  • Oncopeptides
  • ONL Therapeutics
  • Onyx Therapeutics
  • OPKO Health
  • Oramed Pharmaceuticals
  • OrbiMed
  • Otsuka Pharmaceutical
  • Ovoca Bio
  • Oxalo Therapeutics
  • Oxurion
  • PAION
  • Palatin Technologies
  • Park West Asset
  • Partners Innovation Fund
  • PEP-Therapy
  • PeptiDream
  • Peptilogics
  • Peptron
  • Perceptive Xontogeny Venture Fund
  • Pfizer
  • Pfizer Venture Investments
  • Pharma Research Products
  • PharmaMar
  • Pharmstandard International
  • Piedmont Capital Partners
  • PIN Pharma
  • Ping An Ventures
  • Pint Pharma
  • Playground Global
  • PMV
  • Polyphor
  • Pontifax
  • Praxis Pharmaceutical
  • Presight Capital
  • Priavoid
  • proDERM
  • ProLynx-
  • ProMore Pharma
  • ProNeurogen
  • Protagonist Therapeutics
  • PSQ Capital
  • Pulmotect
  • Qilu Pharmaceutical
  • Quaker Partners
  • Quantum Leap Healthcare Collaborative (QLHC)
  • Quartesian
  • Radius Health
  • Rani Therapeutics
  • Rapha Capital Management
  • RegeneRx Biopharmaceuticals
  • ReGenTree
  • Relief Therapeutics
  • ReumaNederland
  • Rhythm Pharmaceuticals
  • Riesner Verwaltungs
  • Roche
  • Rock Springs Capital Management
  • Salem Partners
  • Salix Pharmaceuticals
  • Sanofi
  • Sanofi-Aventis
  • Santhera Pharmaceuticals
  • Sapience Therapeutics
  • Sarsia Seed
  • Satter Medical Technology Partners
  • SciClone Pharmaceuticals
  • Scios (Acquired by Johnson & Johnson)
  • Seachaid Pharmaceuticals
  • Sectoral Asset Management
  • Serpin Pharma
  • Seventure Partners
  • SFJ Pharmaceuticals
  • Shanghai Fosun Pharmaceutical
  • Shire
  • SIRS Therapeutics
  • Société Fédérale de Participations et d'Investissement (SFPI)
  • Société Régionale d'Investissement de Wallonie (SRIW)
  • Soligenix
  • Sophos Capital
  • Soricimed Biopharma
  • Specialised Therapeutics Asia
  • SR One
  • Stealth BioTherapeutics
  • SV Health Investors
  • Swedish Orphan Biovitrum (SOBI)
  • SYNG Pharmaceuticals
  • TaiAn Technologies
  • Takeda
  • Tarsa Therapeutics
  • TearSolutions
  • Technomark Life Sciences
  • TEDCO
  • Televenture (Funded through NIK III)
  • Texas A&M University Health Science Center
  • The Column Group
  • The Leona M. and Harry B. Helmsley Charitable Trust
  • University of Bath
  • The University of Chicago Innovation Fund
  • The University of Texas MD Anderson Cancer Center
  • TheraSource
  • Theratechnologies
  • Third Rock Ventures
  • Topas Therapeutics
  • Tsingyuan Ventures
  • TTY Biopharm
  • TwoToBiotech
  • UCB Pharma
  • University of Freiburg
  • University of Missouri Research Reactor (MURR®)
  • University of St Andrews
  • US Department of Defense
  • UVA Seed Fund
  • ValiRx
  • Vault Pharma
  • Vaxeal
  • venBio Global Strategic Fund
  • VentureHealth
  • Vertex Ventures
  • Vesalius Biocapital
  • Viatem
  • Vifor Pharma
  • Virtus Inspire Ventures
  • Vivo Capital
  • VTC Innovation Fund
  • Wales Life Sciences Fund
  • West Midlands Academic Health Science Network (WMAHSN)
  • Windtree Therapeutics
  • WuXi AppTec
  • Wyvern
  • Xigen
  • YuYang D&U
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll